Accounting for socioeconomic status in risk adjustment can avoid penalizing hospitals with more low-income patients, according to Ashish K. Jha, MD, MPH, the K.T. Li Professor of Health Policy at the Harvard T.H. Chan School of Public Health and the director of the Harvard Global Health Institute.
Accounting for socioeconomic status in risk adjustment can avoid penalizing hospitals with more low-income patients, according to Ashish K. Jha, MD, MPH, the K.T. Li Professor of Health Policy at the Harvard T.H. Chan School of Public Health and the director of the Harvard Global Health Institute.
Transcript (slightly modified)
Why do you think CMS did not factor in the economic well-being of patients as part of the Medicare star ratings program for hospitals? What’s the argument for including that into the rating system?
So there’s been this, I think at times really misguided, debate between some people who think we shouldn’t be adjusting for socioeconomic status, because their argument is that somehow that’s giving hospitals credit for providing bad care to poor people. I think that’s just a misunderstanding of how risk adjustment works. We do risk adjustment, when we do risk adjustment we account for age, but we’re not saying we’re going to give hospitals credit for providing bad care to older people.
What you want to do is—it’s fine to penalize hospitals that provide bad care to poor people, we just don’t want to be penalizing hospitals that take care of more poor people. So if 2 organizations are exactly the same in terms of how well they do for their poor patients, but one hospital has twice as many poor patients as the other, you don’t want to penalize that hospital just because they have more poor people. That’s what the risk adjustment, or the lack of risk adjustment, for socioeconomic status is doing. And I think there are some people within CMS, the people who’ve developed the measures, who have just misunderstood this issue, and I think are really fixated on this idea that we’d be creating 2 different standards of care, which is not necessarily the case.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More